Pharmacogenetics

• 

  Subject Areas on Research

  • A Genetic Response Score for Hydrochlorothiazide Use: Insights From Genomics and Metabolomics Integration. 
  • A Pharmacogenetic Prediction Model of Progression-Free Survival in Breast Cancer using Genome-Wide Genotyping Data from CALGB 40502 (Alliance). 
  • A framework to evaluate the economic impact of pharmacogenomics. 
  • A genome-wide interaction analysis of tricyclic/tetracyclic antidepressants and RR and QT intervals: a pharmacogenomics study from the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) consortium. 
  • A genomewide association study points to multiple loci that predict antidepressant drug treatment outcome in depression. 
  • A genomic approach to improve prognosis and predict therapeutic response in chronic lymphocytic leukemia. 
  • A hub for bench-to-bedside pharmacogenomic-based research. 
  • A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response. 
  • A penalized likelihood approach for investigating gene-drug interactions in pharmacogenetic studies. 
  • A pharmacogenetic investigation of intravenous furosemide in decompensated heart failure: a meta-analysis of three clinical trials. 
  • A pharmacogenetic study of aldehyde oxidase I in patients treated with XK469. 
  • A pharmacogenetic versus a clinical algorithm for warfarin dosing. 
  • A rationale for conducting parallel mechanistic studies in clinical trials of pharmacotherapy. 
  • A recent update of pharmacogenomics in drug-induced severe skin reactions. 
  • A stepwise approach to implementing pharmacogenetic testing in the primary care setting. 
  • ABCB1 (MDR1) polymorphisms and ovarian cancer progression and survival: a comprehensive analysis from the Ovarian Cancer Association Consortium and The Cancer Genome Atlas. 
  • Adding pharmacogenetics information to drug labels: lessons learned. 
  • Advances in pharmacogenomic research and development. 
  • Ancestry and pharmacogenomics of relapse in acute lymphoblastic leukemia. 
  • Anesthesia: a discipline that incorporates clinical pharmacology across the DDRU continuum. 
  • Anthracycline-related cardiomyopathy after childhood cancer: role of polymorphisms in carbonyl reductase genes--a report from the Children's Oncology Group. 
  • Apolipoprotein E and neurological disease: therapeutic potential and pharmacogenomic interactions. 
  • Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology clinical practice guideline. 
  • Association between treatment-emergent suicidal ideation with citalopram and polymorphisms near cyclic adenosine monophosphate response element binding protein in the STAR*D study. 
  • Association of CASP7 polymorphisms and survival of patients with non-small cell lung cancer with platinum-based chemotherapy treatment. 
  • Association of GRIK4 with outcome of antidepressant treatment in the STAR*D cohort. 
  • Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. 
  • Association of human aryl hydrocarbon receptor gene polymorphisms with risk of lung cancer among cigarette smokers in a Chinese population. 
  • Associations of ABCB1 and IL-10 genetic polymorphisms with sirolimus-induced dyslipidemia in renal transplant recipients. 
  • Atenolol induced HDL-C change in the pharmacogenomic evaluation of antihypertensive responses (PEAR) study. 
  • Biomarkers for smoking cessation. 
  • Bucindolol for the Maintenance of Sinus Rhythm in a Genotype-Defined HF Population: The GENETIC-AF Trial. 
  • Bucindolol hydrochloride in atrial fibrillation and concomitant heart failure. 
  • CYP2C19 pharmacogenetics versus standard of care dosing for selecting antiplatelet therapy in patients with coronary artery disease: A meta-analysis of randomized clinical trials. 
  • CYP2D6 drug-gene and drug-drug-gene interactions among patients prescribed pharmacogenetically actionable opioids. 
  • CYP3A4/5 and pharmacogenetics in patients with sarcoma - Authors' reply. 
  • Cancer pharmacogenomics and pharmacoepidemiology: setting a research agenda to accelerate translation. 
  • Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan. 
  • Challenges to integrating pharmacogenetic testing into medication therapy management. 
  • Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotype. 
  • Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants. 
  • Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 update. 
  • Clinical Pharmacogenetics Implementation Consortium guidelines for human leukocyte antigen-B genotype and allopurinol dosing. 
  • Clinical Utilization of Pharmacogenetics in Psychiatry - Perspectives of Pharmacists, Genetic Counselors, Implementation Science, Clinicians, and Industry. 
  • Clinical application of cardiovascular pharmacogenetics. 
  • Clinical application of pharmacogenetics: focusing on practical issues. 
  • Clinical delivery of pharmacogenetic testing services: a proposed partnership between genetic counselors and pharmacists. 
  • Clinical interpretation and implications of whole-genome sequencing. 
  • Clinical pharmacogenomic testing and reporting: A technical standard of the American College of Medical Genetics and Genomics (ACMG). 
  • Combinatorial pharmacogenetic interactions of bucindolol and β1, α2C adrenergic receptor polymorphisms. 
  • Common genetic variation and antidepressant efficacy in major depressive disorder: a meta-analysis of three genome-wide pharmacogenetic studies. 
  • Common risk allele in aromatic antiepileptic-drug induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Han Chinese. 
  • Community pharmacists' experience with pharmacogenetic testing. 
  • Comparison of delivery strategies for pharmacogenetic testing services. 
  • Connecting genetic risk to disease end points through the human blood plasma proteome. 
  • Consensus statement on transcultural issues in depression and anxiety from the International Consensus Group on Depression and Anxiety. 
  • Consideration of patient preferences and challenges in storage and access of pharmacogenetic test results. 
  • Considerations of pharmacogenetic testing in children. 
  • Cost-effectiveness of epidermal growth factor receptor mutation testing and first-line treatment with gefitinib for patients with advanced adenocarcinoma of the lung. 
  • Decrease in high on-treatment platelet reactivity (HPR) prevalence on switching from clopidogrel to prasugrel: insights from the switching anti-platelet (SWAP) study. 
  • Delivering pharmacogenetic testing to the masses: an achievable goal? 
  • Design and rationale of GUARDD-US: A pragmatic, randomized trial of genetic testing for APOL1 and pharmacogenomic predictors of antihypertensive efficacy in patients with hypertension. 
  • Development of biomarkers to optimize pediatric patient management: what makes children different? 
  • Developmental pharmacogenomics. 
  • Do platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents?: platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents. 
  • Dose Response of β-Blockers in Adrenergic Receptor Polymorphism Genotypes. 
  • Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease. 
  • Drug-gene interactions and the search for missing heritability: a cross-sectional pharmacogenomics study of the QT interval. 
  • Dysregulation of innate immunity in hepatitis C virus genotype 1 IL28B-unfavorable genotype patients: impaired viral kinetics and therapeutic response. 
  • Economic analysis of gene expression profile data to guide adjuvant treatment in women with early-stage breast cancer. 
  • Educating patients and providers through comprehensive pharmacogenetic test reports. 
  • Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. 
  • Effect of CYP2C19*2 and *3 loss-of-function alleles on platelet reactivity and adverse clinical events in East Asian acute myocardial infarction survivors treated with clopidogrel and aspirin. 
  • Effect of Pharmacogenomic Testing for Drug-Gene Interactions on Medication Selection and Remission of Symptoms in Major Depressive Disorder: The PRIME Care Randomized Clinical Trial. 
  • Effect of catechol-O-methyltransferase polymorphism on response to propranolol therapy in chronic musculoskeletal pain: a randomized, double-blind, placebo-controlled, crossover pilot study. 
  • Efficacy of the pharmacologic chaperone migalastat in a subset of male patients with the classic phenotype of Fabry disease and migalastat-amenable variants: data from the phase 3 randomized, multicenter, double-blind clinical trial and extension study. 
  • Enteric microbiome metabolites correlate with response to simvastatin treatment. 
  • Estimation of the warfarin dose with clinical and pharmacogenetic data. 
  • Evaluation of a pharmacogenetic educational toolkit for community pharmacists. 
  • Evaluation of the PharmGKB knowledge base as a resource for efficiently assessing the clinical validity and utility of pharmacogenetic assays. 
  • Exploratory planning and implementation of a pilot pharmacogenetic program in a community pharmacy. 
  • Factors influencing uptake of pharmacogenetic testing in a diverse patient population. 
  • Future directions in pharmacogenomics discovery in cardiovascular disease. 
  • Gastric cancer pharmacogenetics: progress or old tripe? 
  • Gene Expression Profiles Link Respiratory Viral Infection, Platelet Response to Aspirin, and Acute Myocardial Infarction. 
  • Gene expression analysis of cardiovascular diseases: novel insights into biology and clinical applications. 
  • Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer. 
  • Genetic and social environment interactions and their impact on health policy. 
  • Genetic lesions in diffuse large B-cell lymphomas. 
  • Genetic markers of suicidal ideation emerging during citalopram treatment of major depression. 
  • Genetic polymorphism and function of glutathione S-transferases in tumor drug resistance. 
  • Genetic profiling and tailored therapy in asthma: are we there yet? 
  • Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. 
  • Genetics in heart failure: practical incorporation of this new biologic dimension. 
  • Genetics. FDA races in wrong direction. 
  • Genome-wide and candidate gene approaches of clopidogrel efficacy using pharmacodynamic and clinical end points-Rationale and design of the International Clopidogrel Pharmacogenomics Consortium (ICPC). 
  • Genome-wide association study of suicidal ideation emerging during citalopram treatment of depressed outpatients. 
  • Genome-wide pharmacogenomic study of neurocognition as an indicator of antipsychotic treatment response in schizophrenia. 
  • Genomewide Association Study of Platelet Reactivity and Cardiovascular Response in Patients Treated With Clopidogrel: A Study by the International Clopidogrel Pharmacogenomics Consortium. 
  • Genomewide Meta-Analysis Validates a Role for S1PR1 in Microtubule Targeting Agent-Induced Sensory Peripheral Neuropathy. 
  • Genomewide pharmacogenomic study of metabolic side effects to antipsychotic drugs. 
  • Genomic and personalized medicine: foundations and applications. 
  • Genomic medicine: a decade of successes, challenges, and opportunities. 
  • Genomic medicine: bringing biomarkers to clinical medicine. 
  • Genomic signatures to guide the use of chemotherapeutics. 
  • Grassroots marketing in a global era: more lessons from BiDil. 
  • Horizon Scan Of Clinical Laboratories Offering Pharmacogenetic Testing. 
  • Human leukocyte antigens and drug hypersensitivity. 
  • Identifying genomic and developmental causes of adverse drug reactions in children. 
  • Immunologic basis for allopurinol-induced severe cutaneous adverse reactions: HLA-B*58:01-restricted activation of drug-specific T cells and molecular interaction. 
  • Implementation of a pharmacogenomics service in a community pharmacy. 
  • Implementing genome-driven personalized cardiology in clinical practice. 
  • Implications of pharmacogenomics for drug development and clinical practice. 
  • Incorporation of pharmacogenetic testing into medication therapy management. 
  • Individualizing pharmacogenomic test results in the context of the microbiome. 
  • Influence of CYP2C19*2 and *3 loss-of-function alleles on the pharmacodynamic effects of standard- and high-dose clopidogrel in East Asians undergoing percutaneous coronary intervention: the results of the ACCEL-DOUBLE-2N3 study. 
  • Influence of genetic polymorphisms on platelet function, response to antiplatelet drugs and clinical outcomes in patients with coronary artery disease. 
  • Integration of molecular diagnostics with therapeutics: implications for drug discovery and patient care. 
  • Integration of pharmacometabolomic and pharmacogenomic approaches reveals novel insights into antiplatelet therapy. 
  • Is genetic testing for cytochrome P450 polymorphisms ready for implementation? 
  • Is primary care ready for pharmacogenetics? 
  • Large-scale pharmacogenomic study of sulfonylureas and the QT, JT and QRS intervals: CHARGE Pharmacogenomics Working Group. 
  • Learning from product labels and label changes: how to build pharmacogenomics into drug-development programs. 
  • Managing Increased Accessibility to Pharmacogenomic Data. 
  • Medical genomics: Gather and use genetic data in health care. 
  • Merging pharmacometabolomics with pharmacogenomics using '1000 Genomes' single-nucleotide polymorphism imputation: selective serotonin reuptake inhibitor response pharmacogenomics. 
  • Metabolomic Signatures for Drug Response Phenotypes: Pharmacometabolomics Enables Precision Medicine. 
  • Methadone Pharmacogenetics: CYP2B6 Polymorphisms Determine Plasma Concentrations, Clearance, and Metabolism. 
  • Methadone pharmacogenetics in vitro and in vivo: Metabolism by CYP2B6 polymorphic variants and genetic variability in paediatric disposition. 
  • MicroSCALE screening reveals genetic modifiers of therapeutic response in melanoma. 
  • Multisite Investigation of Outcomes With Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention. 
  • Mutations linked to drug resistance, human immunodeficiency virus type 1 biologic phenotype and their association with disease progression in children receiving nucleoside reverse transcriptase inhibitors. 
  • New applications of disease genetics and pharmacogenetics to drug development. 
  • New paradigms in cardiovascular medicine: emerging technologies and practices: perioperative genomics. 
  • North Carolina's multi-institutional pharmacogenomics efforts with the North Carolina Precision Health Collaborative. 
  • Nurses' communication of pharmacogenetic test results as part of discharge care. 
  • O6-Methylguanine DNA Methyltransferase Status Does Not Predict Response or Resistance to Alkylating Agents in Well-Differentiated Pancreatic Neuroendocrine Tumors. 
  • On assessing bioequivalence using genomic data with model misspecification. 
  • Oncogenic pathway signatures in human cancers as a guide to targeted therapies. 
  • Optimization of pediatric rheumatology therapeutics. 
  • Pancreatic cancer: translating lessons from mouse models. 
  • Participation in Cancer Pharmacogenomic Studies: A Study of 8456 Patients Registered to Clinical Trials in the Cancer and Leukemia Group B (Alliance). 
  • Patient characteristics, experiences and perceived value of pharmacogenetic testing from a single testing laboratory. 
  • Personalized medicine: progress and promise. 
  • Personalized medicine: revolutionizing drug discovery and patient care. 
  • Pharmacogenetic challenges for the health care system. 
  • Pharmacogenetic determinants of human liver microsomal alfentanil metabolism and the role of cytochrome P450 3A5. 
  • Pharmacogenetic meta-analysis of genome-wide association studies of LDL cholesterol response to statins. 
  • Pharmacogenetic testing in the face of unclear clinical efficacy: lessons from cytochrome P450 2D6 for tamoxifen. 
  • Pharmacogenetic testing: not as simple as it seems. 
  • Pharmacogenetics and safety parameters for platelet P2Y12 receptor antagonists. 
  • Pharmacogenetics goes 3D. 
  • Pharmacogenetics in heart failure trials. 
  • Pharmacogenetics of Clopidogrel: An Unresolved Issue. 
  • Pharmacogenetics of antipsychotic response in the CATIE trial: a candidate gene analysis. 
  • Pharmacogenetics of methylphenidate response in preschoolers with ADHD. 
  • Pharmacogenetics of minimal residual disease response in children with B-precursor acute lymphoblastic leukemia: a report from the Children's Oncology Group. 
  • Pharmacogenetics studies in STAR*D: strengths, limitations, and results. 
  • Pharmacogenetics: Ethical Issues and Policy Options 
  • Pharmacogenomic effects of apolipoprotein e on intracerebral hemorrhage. 
  • Pharmacogenomics and end-organ susceptibility to injury in the perioperative period. 
  • Pharmacogenomics courses in pharmacy school curricula. 
  • Pharmacogenomics for personalized pain medicine. 
  • Pharmacogenomics in cancer therapy: is host genome variability important? 
  • Pharmacogenomics in childhood rheumatic disorders: a foundation for future individualized therapy. 
  • Pharmacogenomics in pediatric rheumatology. 
  • Pharmacogenomics in the nursing literature: an integrative review. 
  • Pharmacogenomics of Bucindolol in Atrial Fibrillation and Heart Failure. 
  • Pharmacogenomics of adverse drug reactions: implementing personalized medicine. 
  • Pharmacogenomics of β-blockers and statins: possible implications for perioperative cardiac complications. 
  • Pharmacogenomics study of thiazide diuretics and QT interval in multi-ethnic populations: the cohorts for heart and aging research in genomic epidemiology. 
  • Pharmacometabolomics reveals racial differences in response to atenolol treatment. 
  • Pilot study of pharmacist-assisted delivery of pharmacogenetic testing in a primary care setting. 
  • Pipeline pharmacogenetics: a novel approach to integrating pharmaco-genetics into drug development. 
  • Polymorphisms in genes encoding drug metabolizing enzymes and their influence on the outcome of children with neuroblastoma. 
  • Potential applications of pharmacogenomics to heart failure therapies. 
  • Potential use of auxiliary labels to promote patient awareness of pharmacogenetic testing. 
  • Practical ethics: establishing a pathway to benefit for complex pharmacogenomic tests. 
  • Precision Medicine: Towards Individualized Dosing in Pediatric Rheumatology. 
  • Precision medicine in addiction research: where has the time gone? 
  • Predictors of consent to pharmacogenomics testing in the IDEAL study. 
  • Primary care physicians' knowledge of and experience with pharmacogenetic testing. 
  • Professional perspectives about pharmacogenetic testing and managing ancillary findings. 
  • Proposal for a pharmacogenetics certificate program for pharmacists. 
  • Prospective dosing of warfarin based on cytochrome P-450 2C9 genotype. 
  • Prospects for personalized cardiovascular medicine: the impact of genomics. 
  • Public attitudes toward ancillary information revealed by pharmacogenetic testing under limited information conditions. 
  • Public perspectives about pharmacogenetic testing and managing ancillary findings. 
  • Quantitative trait locus and computational mapping identifies Kcnj9 (GIRK3) as a candidate gene affecting analgesia from multiple drug classes. 
  • Recent developments in clopidogrel pharmacology and their relation to clinical outcomes. 
  • Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. 
  • Research Directions in the Clinical Implementation of Pharmacogenomics: An Overview of US Programs and Projects. 
  • Role of genotype-based personalized antiplatelet therapy in the era of potent P2Y₁₂ receptor inhibitors. 
  • Sleep Pharmacogenetics: The Promise of Precision Medicine. 
  • Some aspects of analysis of gene array data. 
  • Sphingolipid Metabolic Pathway Impacts Thiazide Diuretics Blood Pressure Response: Insights From Genomics, Metabolomics, and Lipidomics. 
  • Steroid-induced ocular hypertension/glaucoma: Focus on pharmacogenomics and implications for precision medicine. 
  • Stevens-Johnson syndrome induced by the cross-reactivity between teicoplanin and vancomycin. 
  • Striking a balance in communicating pharmacogenetic test results: promoting comprehension and minimizing adverse psychological and behavioral response. 
  • Survey of US public attitudes toward pharmacogenetic testing. 
  • Survey of genetic counselors and clinical geneticists' use and attitudes toward pharmacogenetic testing. 
  • Systems Pharmacogenomics Finds RUNX1 Is an Aspirin-Responsive Transcription Factor Linked to Cardiovascular Disease and Colon Cancer. 
  • TSPAN5, ERICH3 and selective serotonin reuptake inhibitors in major depressive disorder: pharmacometabolomics-informed pharmacogenomics. 
  • Tamoxifen pharmacogenomics: the role of CYP2D6 as a predictor of drug response. 
  • Targeted therapies for cancer 2004. 
  • Testing gene-treatment interactions in pharmacogenetic studies. 
  • The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. 
  • The FKBP5-gene in depression and treatment response--an association study in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) Cohort. 
  • The IGNITE Pharmacogenetics Working Group: An Opportunity for Building Evidence with Pharmacogenetic Implementation in a Real-World Setting. 
  • The Personalized Medicine Coalition: goals and strategies. 
  • The Pharmacogenomics of Anti-Platelet Intervention (PAPI) Study: Variation in Platelet Response to Clopidogrel and Aspirin. 
  • The clinical pharmacogenetics implementation consortium guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update. 
  • The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy. 
  • The convergence of herb pharmacodynamics and herb-drug interactions on hemostasis. 
  • The effect of aprepitant and race on the pharmacokinetics of cyclophosphamide in breast cancer patients. 
  • The functional G143E variant of carboxylesterase 1 is associated with increased clopidogrel active metabolite levels and greater clopidogrel response. 
  • The heritability of antinociception: common pharmacogenetic mediation of five neurochemically distinct analgesics. 
  • The influence of CYP2C19 polymorphisms on the pharmacokinetics, pharmacodynamics, and clinical effectiveness of P2Y(12) inhibitors. 
  • The integration of molecular diagnostics with therapeutics. Implications for drug development and pathology practice. 
  • The long and winding road to warfarin pharmacogenetic testing. 
  • The path to personalized medicine. 
  • The pharmacogenetics of antiplatelet agents: towards personalized therapy? 
  • The pharmacogenetics of coumarin therapy. 
  • The potential impact of pharmacogenetic testing on medication adherence. 
  • The potential of a placebo/nocebo effect in pharmacogenetics. 
  • The relationship of polymorphisms in ABCC2 and SLCO1B3 with docetaxel pharmacokinetics and neutropenia: CALGB 60805 (Alliance). 
  • The use of single-nucleotide polymorphism maps in pharmacogenomics. 
  • The worry about clopidogrel "nonresponsiveness": identification and treatment in the post-percutaneous coronary intervention patient. 
  • Toward a Definition of "No Meaningful Benefit" From Antidepressant Treatment: An Equipercentile Analysis With Cross-Trial Validation Across Multiple Rating Scales. 
  • Transformation of alkylating regimen of thiotepa into tepa determines the disease progression through GSTP1 gene polymorphism for metastatic breast cancer patients receiving thiotepa containing salvage chemotherapy. 
  • Translating genomic biomarkers into clinically useful diagnostics. 
  • Understanding the state of pharmacogenomic testing for thiopurine methyltransferase within a large health system. 
  • United States Emergency Department Use of Medications with Pharmacogenetic Recommendations. 
  • Use of Pharmacogenetic Information in the Treatment of Cardiovascular Disease. 
  • Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. 
  • Use of pharmacogenetics to guide warfarin therapy. 
  • Using Stepwise Pharmacogenomics and Proteomics to Predict Hepatitis C Treatment Response in Difficult to Treat Patient Populations. 
  • Using pharmacogenetics to improve drug safety and efficacy. 
  • VKORC1 haplotypes in five East-Asian populations and Indians. 
  • What is the role of pharmacogenetics in clinical psychiatry? 
  • Where the rubber meets the road in pharmacogenetics: assessment of gene-environment interactions. 
• 

  Keywords of People

  • Allen LaPointe, Nancy Marie, Adjunct Associate Professor in the Department of Medicine, Medicine, Cardiology
  • Berchuck, Andrew, James M. Ingram Distinguished Professor of Gynecologic Oncology, Obstetrics and Gynecology, Gynecologic Oncology
  • Cho, Alex Han, Associate Professor of Medicine, Medicine, General Internal Medicine
  • James, Michael Lucas, Professor of Anesthesiology, Anesthesiology
  • Laskowitz, Daniel Todd, Professor of Neurology, Duke Science & Society
  • O'Connor, Christopher Michael, Adjunct Professor in the Department of Medicine, Medicine, Clinical Pharmacology
  • Orlando, Lori Ann, Professor of Medicine, Medicine, General Internal Medicine
  • Voora, Deepak, Associate Professor of Medicine, Medicine, Cardiology